FDA: Cyramza Approval Now Includes Non-Small-Cell Lung CA

Share this content:
FDA: Cyramza Approval Now Includes Non-Small-Cell Lung CA
FDA: Cyramza Approval Now Includes Non-Small-Cell Lung CA

(HealthDay News) -- U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small-cell lung cancer (NSCLC), the agency said Friday.

Cyramza is designed to block the blood supply that feeds tumors. It's intended for people whose tumors have grown during or after treatment with other drugs.

Cyramza was first approved in April to treat advanced stomach cancer or gastroesophageal junction (GEJ) adenocarcinoma, and approval was widened in November to include advanced gastric or GEJ adenocarcinoma in combination with paclitaxel.

Clinical side effects have included neutropenia, stomatitis, fatigue, severe bleeding, blood clots, raised blood pressure, and impaired wound healing.

Cyramza is marketed by Eli Lilly, based in Indianapolis.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves First Generic EpiPen

FDA Approves First Generic EpiPen

Approval will address both rising costs and shortages of epinephrine

Report Details Corneal Infection Tied to Sleeping in Contacts

Report Details Corneal Infection Tied to Sleeping in ...

Six patients reported sleeping in lenses on regular basis; most had vision loss, permanent damage

Honey May Protect Children Who Swallow Button Batteries

Honey May Protect Children Who Swallow Button Batteries

Honey and Carafate appear to rapidly protect against batteries' caustic effects

is free, fast, and customized just for you!




Already a member?

Sign In Now »